Last updated: September 7, 2026
Yescarta, Gilead Sciences’ axicabtagene ciloleucel, is the leading commercial CD19-directed CAR-T therapy by revenue. Its U.S. biologic exclusivity runs through October 2029, although patent protection, regulatory exclusivity and market access vary by jurisdiction. Revenue growth has been driven by broader lymphoma indications, improved manufacturing capacity and earlier-line treatment use. Key risks are competition from Breyanzi and other CAR-T products, manufacturing constraints, reimbursement complexity, treatment-center capacity and eventual biosimilar competition.
What is Yescarta and which indications drive demand?
Yescarta is an autologous CAR-T cell therapy manufactured by Kite, a Gilead company. It collects a patient’s T cells, genetically modifies them to express a CD19-directed chimeric antigen receptor, expands the cells and reinfuses them after lymphodepleting chemotherapy.
The FDA originally approved Yescarta in October 2017 for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The label later expanded into earlier-line large B-cell lymphoma and follicular lymphoma.
| FDA milestone |
Indication |
| October 18, 2017 |
Relapsed or refractory large B-cell lymphoma after at least two systemic therapies |
| April 2022 |
Second-line treatment for large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months |
| March 2021 |
Relapsed or refractory follicular lymphoma after at least two lines of systemic therapy under an accelerated approval pathway |
| 2024 |
Conversion of the follicular lymphoma indication to regular approval following confirmatory evidence |
Yescarta’s largest commercial market remains aggressive B-cell lymphoma, particularly diffuse large B-cell lymphoma. The second-line indication materially increased its addressable population because patients with early relapse or primary refractory disease can receive CAR-T instead of proceeding directly to conventional salvage chemotherapy and autologous stem-cell transplantation.
How large is the Yescarta market?
Yescarta competes in the commercial CAR-T market, which has expanded from a small niche into a multibillion-dollar cell therapy segment. The main products in hematologic malignancies are:
| Product |
Active technology |
Company |
Principal market |
| Yescarta |
Axicabtagene ciloleucel, CD19 CAR-T |
Kite/Gilead |
Large B-cell lymphoma, follicular lymphoma |
| Tecartus |
Brexucabtagene autoleucel, CD19 CAR-T |
Kite/Gilead |
Mantle cell lymphoma, B-cell acute lymphoblastic leukemia |
| Breyanzi |
Lisocabtagene maraleucel, CD19 CAR-T |
Bristol Myers Squibb |
Large B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma |
| Kymriah |
Tisagenlecleucel, CD19 CAR-T |
Novartis |
Pediatric and young-adult B-cell acute lymphoblastic leukemia, lymphoma |
| Abecma |
Idecabtagene vicleucel, BCMA CAR-T |
Bristol Myers Squibb and 2seventy bio |
Multiple myeloma |
| Carvykti |
Ciltacabtagene autoleucel, BCMA CAR-T |
Johnson & Johnson and Legend Biotech |
Multiple myeloma |
Yescarta has benefited from a large eligible patient population in aggressive lymphoma and from earlier-line approval. Breyanzi is its closest direct competitor in large B-cell lymphoma. Kymriah competes in some lymphoma settings but has a smaller commercial position in adult large B-cell lymphoma.
Commercial adoption depends on more than label breadth. Treatment requires certified centers, leukapheresis, manufacturing slots, bridging therapy, lymphodepletion and monitoring for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The number of qualified treatment centers and the ability to discharge patients to outpatient care affect market penetration.
What is Yescarta’s financial trajectory?
Gilead has reported sustained year-over-year growth in Yescarta product sales. Public company reporting generally provides product revenue but not a full product-level profit-and-loss statement.
| Fiscal year |
Approximate Yescarta revenue |
Growth profile |
| 2020 |
$563 million |
Early commercial expansion |
| 2021 |
$695 million |
Continued uptake in relapsed lymphoma |
| 2022 |
$1.16 billion |
Significant benefit from earlier-line use |
| 2023 |
$1.57 billion |
Strong volume growth and broader adoption |
| 2024 |
Approximately $1.6 billion to $1.7 billion |
Continued growth, with a more mature base |
Sources include Gilead annual reports and fourth-quarter earnings disclosures. Revenue figures can vary slightly depending on reporting revisions and presentation format (Gilead Sciences, 2021, 2022, 2023, 2024).
The revenue trajectory has four principal drivers:
- Earlier-line use in large B-cell lymphoma.
- Expansion into follicular lymphoma.
- Higher physician familiarity with CAR-T referral and treatment.
- Manufacturing and logistics improvements.
The principal limitations are treatment-center throughput, patient eligibility, clinical deterioration before infusion, payer authorization and adverse-event management. These constraints make Yescarta revenue more capacity-dependent than a conventional oral oncology drug.
What is Yescarta’s revenue exposure to lymphoma?
Yescarta is highly concentrated in hematologic oncology. Unlike diversified pharmaceutical products, it does not have multiple unrelated therapeutic areas to offset a decline in one indication. Large B-cell lymphoma remains the economic core, while follicular lymphoma provides an additional long-term growth channel.
The second-line label is commercially important because it shifts Yescarta closer to the front of the treatment pathway. Earlier use increases the theoretical patient pool, but it also places Yescarta against intensive chemotherapy, transplantation and competing CAR-T products. Market share, not simply label expansion, will determine the incremental revenue.
When does Yescarta lose U.S. exclusivity?
Yescarta received FDA approval on October 18, 2017. The reference biologic exclusivity period under the Biologics Price Competition and Innovation Act is 12 years from first licensure. The principal U.S. reference-product exclusivity date is therefore October 18, 2029.
| Exclusivity type |
Relevant date or period |
Commercial effect |
| U.S. reference biologic exclusivity |
October 18, 2029 |
Biosimilar approval cannot rely on the reference product before this date |
| U.S. pediatric exclusivity |
No publicly established six-month extension identified |
No confirmed extension to the 12-year period |
| Orphan exclusivity |
Applies by indication and timing |
Can restrict approval of the same drug for the same orphan use |
| Patent protection |
Patent-specific |
May extend beyond biologic exclusivity if valid and enforceable |
| EU data exclusivity |
Generally eight years from authorization |
Regulatory protection followed by marketing protection |
| EU market protection |
Generally two years after data exclusivity |
Possible one-year extension for a qualifying new indication |
Biologic exclusivity does not guarantee market exclusivity through 2029 in every jurisdiction. It also does not determine whether a competitor can launch through a separate biologic, a non-reference manufacturing route or a licensed arrangement.
What patents protect Yescarta?
Yescarta’s protection is spread across biologic exclusivity, CAR-T construct technology, manufacturing processes, cell expansion, formulation, administration and use claims. The complete commercial patent estate is not equivalent to a conventional small-molecule Orange Book listing.
The FDA does not list biologic patents for Yescarta in the Orange Book because Yescarta is licensed under a biologics license application rather than a traditional new drug application. Patent information for biologics is handled through BPCIA procedures, including the patent dance, confidential exchanges and litigation under 35 U.S.C. § 271(e)(6).
Publicly relevant patent categories include:
- CD19 CAR constructs and antigen-binding domains.
- T-cell activation and costimulatory domains.
- Viral transduction and cell-engineering methods.
- Cell expansion and culture conditions.
- Cryopreservation and thawing processes.
- Patient-selection and treatment methods.
- Combination use with chemotherapy or immunotherapy.
- Manufacturing controls and release testing.
Kite’s patents and licenses also must be analyzed against third-party CAR-T rights. One major litigation matter was Juno Therapeutics v. Kite Pharma involving U.S. Patent No. 7,446,190, which covered aspects of CAR-T technology. The Federal Circuit held the patent invalid for lack of written description in 2023 after earlier damages proceedings and Supreme Court review activity. The case was important to the broader CAR-T freedom-to-operate environment, but it was not a conventional challenge to Yescarta’s FDA approval or a direct Paragraph IV case against an Yescarta generic (Juno Therapeutics, Inc. v. Kite Pharma, Inc., 2023).
A valid patent may extend protection beyond October 2029, but patent expiration must be assessed patent by patent. Patent term adjustment, terminal disclaimers, continuations, maintenance status and claim scope affect the practical date. A single patent expiry date should not be treated as the end of Yescarta exclusivity.
What is the Orange Book and Purple Book status of Yescarta?
Yescarta does not have a standard Orange Book patent listing because it is a biologic. Its FDA regulatory record is associated with BLA 125643. The FDA Purple Book identifies licensed biological products and reference products relevant to biosimilar and interchangeable-product analysis.
| Regulatory item |
Yescarta status |
| FDA product |
Yescarta |
| Active ingredient |
Axicabtagene ciloleucel |
| Application type |
Biologics license application |
| BLA |
125643 |
| Reference product |
Yes, for biosimilar analysis |
| Orange Book listing |
Not the governing patent-listing mechanism |
| Purple Book relevance |
Identifies the licensed biologic reference product |
| Biosimilar pathway |
BPCIA, subject to approval, exclusivity and patent requirements |
The absence of an Orange Book listing does not mean the product lacks patent protection. It means the patent-disclosure and litigation framework differs from the one used for small-molecule drugs.
Are there Paragraph IV challenges or biosimilar risks for Yescarta?
No publicly established conventional Paragraph IV challenge to Yescarta has become a major market event. Paragraph IV certifications are associated with abbreviated new drug applications for small-molecule products. A biosimilar applicant would generally proceed under the BPCIA rather than file an ANDA with a Paragraph IV certification.
The practical biosimilar risk is delayed compared with small molecules because:
- Manufacturing is patient-specific and technologically complex.
- A biosimilar must demonstrate high similarity to a living-cell product.
- Product comparability includes phenotype, potency, transduction and functional activity.
- Commercial manufacturing requires specialized facilities and validated chain-of-identity controls.
- Substitution rules are different from those for interchangeable small-molecule generics.
- Treatment centers may be reluctant to switch a complex therapy solely for price.
A biosimilar could still pressure price and contracting after reference exclusivity expires. The first entrant may seek a narrow market strategy based on payer discounts, hospital contracts or manufacturing capacity rather than pharmacy substitution.
Which companies are challenging Yescarta commercially?
The most direct competition comes from Bristol Myers Squibb’s Breyanzi. Both products target CD19-positive B-cell malignancies and compete in large B-cell lymphoma. Their competitive differences include manufacturing design, turnaround time, clinical data, toxicity management, treatment-center experience and payer contracting.
| Competitive factor |
Yescarta |
Breyanzi |
| Sponsor |
Kite/Gilead |
Bristol Myers Squibb |
| Core target |
CD19 |
CD19 |
| Major lymphoma market |
Large B-cell lymphoma |
Large B-cell lymphoma |
| Earlier-line positioning |
Established second-line use |
Expanded second-line presence |
| Commercial strength |
First-mover scale and broad center experience |
Competitive manufacturing and label expansion |
| Key risk |
Capacity, toxicity and competitor share loss |
Need to displace an established leader |
Kymriah remains relevant in selected lymphoma and leukemia populations. Tecartus provides Kite with infrastructure and physician relationships but is not a direct substitute across all indications. Pipeline competition includes next-generation CAR-T therapies, allogeneic cell therapies, bispecific antibodies and other off-the-shelf immune therapies.
Bispecific antibodies are especially important because they can be delivered without leukapheresis and individualized manufacturing. They may compete with CAR-T in patients who need rapid treatment or cannot wait for manufacturing.
How strong is the Yescarta patent and commercial estate?
Yescarta’s commercial estate is stronger than its patent estate alone suggests because the product combines regulatory protection with manufacturing complexity and clinical infrastructure.
| Asset |
Strength assessment |
| U.S. biologic exclusivity |
Strong through October 2029 |
| Product differentiation |
Moderate to strong in large B-cell lymphoma |
| Manufacturing barrier |
Strong; patient-specific production limits rapid imitation |
| Clinical-center network |
Strong but replicable by major oncology companies |
| Patent position |
Potentially meaningful, but claim-by-claim analysis is required |
| Biosimilar barrier |
High before 2029; moderate after exclusivity and patent resolution |
| Pricing durability |
Vulnerable to competing CAR-T and bispecific contracting |
| Regulatory moat |
Strong due to clinical and manufacturing requirements |
The most durable barrier is the integrated manufacturing and treatment system. Patent claims can be challenged, designed around or invalidated. Manufacturing know-how, validated release assays, center relationships and treatment protocols are harder to replicate quickly.
What generic or biosimilar launch scenarios exist?
Yescarta is unlikely to face a conventional generic launch. The relevant scenarios are:
Scenario 1: No biosimilar before 2029
This is the baseline regulatory scenario because reference biologic exclusivity blocks reliance on Yescarta’s data before October 2029.
Scenario 2: Biosimilar launch after 2029 with patent litigation
A biosimilar applicant could seek approval after exclusivity, while patent disputes continue over construct, manufacturing or use claims. Launch timing would depend on settlement terms and injunction risk.
Scenario 3: Competitive erosion without a biosimilar
Breyanzi, bispecific antibodies and other CAR-T products could reduce Yescarta utilization before any biosimilar reaches the market. This is the most immediate competitive threat.
Scenario 4: Indication-specific erosion
A competitor may gain share in second-line lymphoma or follicular lymphoma while Yescarta retains strength in other settings. Label-specific clinical preferences could produce different erosion rates by indication.
What licensing deals and manufacturing relationships affect Yescarta?
Yescarta originated from Kite Pharma, which Gilead acquired in 2017 for approximately $11.9 billion. The transaction gave Gilead a commercial CAR-T platform, Kite’s manufacturing capabilities and a portfolio of cell therapy programs (Gilead Sciences, 2017).
Yescarta also operates within a broader ecosystem of:
- Academic research licenses.
- Viral-vector and gene-engineering suppliers.
- Contract manufacturing and logistics providers.
- Certified treatment centers.
- Payer and hospital purchasing arrangements.
- Technology licenses related to CAR design and cell processing.
The Kite acquisition remains the central strategic transaction. It converted Gilead’s oncology strategy from a conventional small-molecule and antiviral model into one that includes high-value individualized cell therapies.
What regulatory and geographic factors affect Yescarta?
The United States is the largest commercial market, supported by FDA approvals, Medicare coverage for eligible indications and a large network of certified centers. Europe, Japan and other markets add revenue but have more variable reimbursement, hospital capacity and treatment pathways.
Geographic barriers include:
- National health technology assessment requirements.
- Hospital budget limits.
- Centralized reimbursement negotiations.
- Limited certified treatment centers.
- Cross-border shipping and chain-of-identity controls.
- Different rules for outpatient administration.
- Uneven access to intensive care and toxicity management.
Manufacturing localization can improve supply resilience but increases fixed costs. The product requires coordination from leukapheresis through final infusion. Delays at any stage can cause patient attrition, especially in aggressive lymphoma.
What litigation affects Yescarta?
The most commercially relevant litigation risk is not a routine generic patent case. It is the broader validity and freedom-to-operate environment for CAR-T technology.
The Juno v. Kite litigation involved U.S. Patent No. 7,446,190 and addressed written-description requirements for CAR-T patent claims. The Federal Circuit’s 2023 decision invalidated the patent, reducing one third-party patent risk for Kite but also demonstrating the vulnerability of broad CAR-T claims (Juno Therapeutics, Inc. v. Kite Pharma, Inc., 2023).
Future disputes could involve:
- CAR architecture and costimulatory domains.
- Antibody-derived binding regions.
- Viral vectors.
- T-cell activation methods.
- Manufacturing processes.
- Use in specific lymphoma populations.
- Biosimilar patent litigation after 2029.
Key Takeaways
- Yescarta is Gilead’s leading CAR-T product and a major commercial asset.
- Revenue increased from approximately $563 million in 2020 to roughly $1.6 billion to $1.7 billion in 2024.
- U.S. reference biologic exclusivity runs through October 18, 2029.
- Yescarta is governed by BLA and BPCIA rules, not conventional Orange Book patent listing procedures.
- Breyanzi is the closest direct commercial competitor in large B-cell lymphoma.
- Bispecific antibodies are a significant non-biosimilar threat because they avoid individualized manufacturing.
- Manufacturing capacity, treatment-center access and reimbursement are as important as patent protection.
- A conventional generic launch is not expected. Future erosion is more likely to begin with competing branded therapies and later involve biosimilar litigation.
- Yescarta’s strongest barriers are regulatory exclusivity, manufacturing know-how, clinical infrastructure and physician experience.
FAQs
What is the active ingredient in Yescarta?
The active ingredient is axicabtagene ciloleucel, an autologous CD19-directed CAR-T cell therapy.
Is Yescarta a biosimilar?
No. Yescarta is an FDA-licensed reference biologic and is not a biosimilar to another CAR-T product.
Can Yescarta be substituted automatically at the pharmacy?
No. Yescarta is an individualized cell therapy administered through specialized treatment centers, not a conventional pharmacy-substitutable product.
What is the biggest threat to Yescarta revenue?
The largest near-term threat is branded competition from Breyanzi and other CAR-T or bispecific therapies, rather than a traditional generic product.
Does Yescarta’s patent protection end in 2029?
Not necessarily. October 2029 is the principal U.S. reference biologic exclusivity date. Patent terms may extend beyond that date, depending on the specific patents, claims, continuations and enforceability.
References
-
U.S. Food and Drug Administration. (2017). FDA approves CAR-T cell therapy to treat certain children and young adults with B-cell acute lymphoblastic leukemia. FDA.
-
U.S. Food and Drug Administration. (2024). Yescarta prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Gilead Sciences, Inc. (2017). Gilead Sciences to acquire Kite Pharma for $11.9 billion. Gilead Sciences.
-
Gilead Sciences, Inc. (2021). 2020 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2022). 2021 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2023). 2022 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2024). 2023 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2025). 2024 annual report. Gilead Sciences.
-
Juno Therapeutics, Inc. v. Kite Pharma, Inc., 55 F.4th 1358 (Fed. Cir. 2023).
